The cost utility of pemetrexed as first-line therapy for advanced non-small cell lung cancer appears to be hindered by p

  • PDF / 140,313 Bytes
  • 1 Pages / 623.591 x 841.847 pts Page_size
  • 68 Downloads / 141 Views

DOWNLOAD

REPORT

3/10/0591-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

PharmacoEconomics & Outcomes News 14 Nov 2009 No. 591

1

Data Loading...

Recommend Documents
Telithromycin appears to be cost effective for CAP

145 35 118KB

Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer

139 9 805KB

The effect of lysyl oxidase polymorphism on susceptibility and prognosis of nonsmall cell lung cancer

191 43 135KB

Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy

230 53 2MB

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer

215 27 612KB

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma pat

140 37 759KB

4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer

144 53 850KB

Chemoradiation therapy for non-small cell lung cancer exacerbates thoracic aortic calcification determined by computed t

142 70 885KB

Small Cell Lung Cancer

160 89 14MB

Image-Guided Radiation Therapy for Lung Cancer

166 31 34MB

Small Cell Lung Cancer and Molecular Targeted Therapy

156 39 297KB

Cell-Based Therapy for Severe COVID-19 Patients: Clinical Trials and Cost-Utility

169 94 926KB